home / stock / crpof / crpof quote
Last: | $0.17 |
---|---|
Change Percent: | 0.0% |
Open: | $0.17 |
Close: | $0.17 |
High: | $0.17 |
Low: | $0.17 |
Volume: | 6,000 |
Last Trade Date Time: | 05/31/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$0.17 | $0.17 | $0.17 | $0.17 | $0.17 | 6,000 | 05-31-2024 |
$0.195495 | $0.195495 | $0.195495 | $0.195495 | $0.195495 | 240 | 05-29-2024 |
$0.2003 | $0 | $0.2003 | $0 | $0 | 56,500 | 05-24-2024 |
$0.2003 | $0.1994 | $0.2003 | $0.2003 | $0.1994 | 730 | 05-21-2024 |
$0.20245 | $0.20245 | $0.20245 | $0.20245 | $0.20245 | 1,000 | 05-17-2024 |
$0.1985 | $0.20595 | $0.1985 | $0.20595 | $0.1985 | 7,000 | 05-16-2024 |
$0.22 | $0.22 | $0.22 | $0.22 | $0.22 | 300 | 05-15-2024 |
$0.192 | $0.1858 | $0.192 | $0.192 | $0.1858 | 9,000 | 05-14-2024 |
$0.183 | $0.183 | $0.183 | $0.183 | $0.183 | 3,000 | 05-13-2024 |
$0.183 | $0.183 | $0.183 | $0.183 | $0.183 | 13,000 | 05-10-2024 |
$0.1845 | $0.1845 | $0.1845 | $0.1845 | $0.1845 | 650 | 04-22-2024 |
$0.1771 | $0.180628 | $0.1771 | $0.180628 | $0.1771 | 6,451 | 04-15-2024 |
$0.181313 | $0.181313 | $0.181313 | $0.181313 | $0.181313 | 500 | 04-11-2024 |
$0.1829 | $0.1829 | $0.1829 | $0.1829 | $0.1829 | 1,000 | 04-04-2024 |
$0.17501 | $0.17501 | $0.17501 | $0.17501 | $0.17501 | 1,400 | 04-03-2024 |
$0.1669 | $0.1669 | $0.1669 | $0.1669 | $0.1669 | 5,000 | 03-26-2024 |
$0.17095 | $0.166947 | $0.17095 | $0.17095 | $0.166947 | 193,500 | 03-25-2024 |
$0.1618 | $0 | $0.1618 | $0 | $0 | 30 | 03-14-2024 |
$0.1618 | $0.1619 | $0.1618 | $0.1619 | $0.1618 | 41,000 | 03-08-2024 |
$0.17338 | $0.17565 | $0.17338 | $0.17565 | $0.17338 | 29,000 | 03-07-2024 |
News, Short Squeeze, Breakout and More Instantly...
TORONTO and EDMONTON, Alberta, June 03, 2024 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”) and Ceapro Inc. (TSX-V: CZO) (OTCQX: CRPOF) (“Ceapro”), two innovative biopharmaceutical development companies, ...
– Q1 2024 marked by significant advancement of R&D projects focused on avenanthramide Phase 1-2a clinical study and the processing of yeast beta glucan along with the building of pilot scale units for PGX Technology – Q1 2024 sales of $2,800,000 vs $3,500,0...
Faraday Future Intelligent Electric Inc. (FFIE) is expected to report for Q1 2024 D-Market Electronic Services & Trading (HEPS) is expected to report for Q1 2024 Christian Dior SE ADR (CHDRY) is expected to report for Q1 2024 Check-Cap Ltd. (CHEK) is expected to report $-0.17 for ...